NIAID Renews Consortium for Food Allergy Research in Its 19th Year

NIAID Now |

NIAID has awarded 11 new cooperative agreements to support the Consortium for Food Allergy Research, or CoFAR, in the latest renewal of the program since its establishment 19 years ago. The institute expects to fund the awards with more than $11 million annually for seven years, contingent upon the availability of funds. 

CoFAR’s goal is to conduct groundbreaking clinical research on food allergy prevention and therapy and on the biological mechanisms underlying food allergy. Conducting clinical research with a consortium of multiple study sites enables investigators to pursue questions that can only be answered through the participation of high numbers of study volunteers. Consortia also can potentially recruit a more diverse set of study participants than any single site could. 

Most recently, CoFAR’s OUtMATCH clinical trial found that treatment with omalizumab (Xolair) substantially increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without experiencing an allergic reaction. The Food and Drug Administration approved Xolair for people with food allergy based on the study findings. 

The new awards will support consortium-wide clinical research projects, which may include treatment or prevention clinical trials. The selection process for these consortium-wide projects began in March 2024. The awards also will support local food allergy-related clinical studies conducted by individual CoFAR sites and the completion of the remaining stages of the OUtMATCH trial. 

The awards have been issued to the following institutions as one leadership center and ten clinical research centers:

Leadership Center

Johns Hopkins University (JHU) 

Principal Investigators: Robert A. Wood (JHU); Supinda Bunyavanich and Scott H. Sicherer (Icahn School of Medicine at Mount Sinai) 
Grant number UM1-AI182034-01

Clinical Research Centers

Arkansas Children's Hospital Research Institute 

Principal Investigator: Stacie M. Jones 
Grant number U01-AI181962-01

Boston Children's Hospital 

Principal Investigator: Rima Rachid 
Grant number U01-AI181964-01

Cincinnati Children's Hospital Medical Center 

Principal Investigators: Amal Halim Assa’ad, Marc E. Rothenberg 
Grant number U01-AI181966-01

Icahn School Of Medicine at Mount Sinai 

Principal Investigator: Scott H. Sicherer 
Grant number U01-AI181883-01

Johns Hopkins University  

Principal Investigator: Robert A. Wood 
Grant number U01-AI182032-01

Northwestern University at Chicago 

Principal Investigators: Ruchi S. Gupta, Maria Cecilia Berin 
Grant number U01-AI181897-01

Stanford University 

Principal Investigators: Sayantani B. Sindher, R. Sharon Chinthrajah  
Grant number U01-AI182039-01

University of Michigan at Ann Arbor 

Principal Investigators: James R. Baker, Johann Eli Gudjonsson, Charles F. Schuler 
Grant number U01-AI181882-01

University of North Carolina Chapel Hill 

Principal Investigators: Edwin Kim, Corinne Keet 
Grant number U01-AI182033-01

Vanderbilt University Medical Center 

Principal Investigators: Leonard B. Bacharier, Rachel Glick Robison 
Grant number U01-AI181927-01

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog

Registry for Asthma Characterization and Recruitment 3 (RACR3) (NCT05272241)

There is a need for people to take part in research studies to learn more about diseases and how to treat them. RACR3 will create a database of participants of all ages with asthma and nasal allergies, or risk factors for these conditions, who are potentially eligible for future CAUSE trials.

Contact Information

Contact recruitment locations.

Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents (PANDA) (NCT05347771)

Prevention of asthma exacerbations is one of the primary goals of current asthma therapy. New treatment modalities such as biologics are playing an increasing role in asthma management as adjunctive therapy. PANDA is a multi-center, double-blind, placebo-controlled, randomized trial of the biologic dupilumab as adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with mostly allergic asthma.

Contact Information

Contact recruitment locations.

Antibody Reduces Allergic Reactions to Multiple Foods in NIH Trial

A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a late-stage clinical trial.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

In People with Stable Lupus, Tapering Immunosuppressant Linked to Low Flare Risk

NIAID Now |

NIH Trial Gives People with Lupus Data to Inform Treatment Decisions 

In people with a form of lupus called systemic lupus erythematosus (SLE), the risk for a severe flare-up of disease was low for both individuals who tapered off long-term immunosuppressive therapy and those who remained on it, a clinical trial has found. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the trial. The findings were reported today in the journal The Lancet Rheumatology.

SLE is a chronic autoimmune disease in which the immune system attacks healthy tissues and organs.  An estimated 450,000 people in the United States have the disease. Medications that doctors prescribe for people with SLE help suppress or tamp down their overactive immune systems. One of the most prescribed immunosuppressants for SLE, mycophenolate mofetil or MMF, effectively treats moderate and severe forms of the disease but also increases the risk of infections, cancers, severe birth defects, miscarriage, and impaired responses to vaccines when the drug is used long-term. Tapering off MMF once SLE symptoms subside reduces these side effects but could risk exposing the individual to a disease flare with the potential to cause a range of symptoms, including fatigue, rash, arthritis and internal organ damage. 

Until today's report, little evidence existed to help people with SLE and their physicians understand the likelihood of a flare after tapering off MMF. The new findings will help people with SLE make informed decisions about withdrawing treatment based on their personal circumstances and risk tolerance. 

The NIAID-funded Autoimmunity Centers of Excellence network conducted the trial under the leadership of Judith A. James, M.D., Ph.D., and Eliza F. Chakravarty, M.D. Dr. James is professor and chair of the Arthritis & Clinical Immunology Research Program at the Oklahoma Medical Research Foundation. Dr. Chakravarty was an associate professor in the same program during the study. The National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of NIH, supports the database for the biological samples processed during the trial.

The trial involved 102 people with SLE ages 18 to 70 whose symptoms had subsided after treatment with MMF. Participants had been taking the drug for an average of 6.6 years. Eighty-four percent of participants were female, reflecting the disproportionate prevalence of lupus in women. Seventy-six percent of participants had a history of lupus nephritis—kidney inflammation that can harm kidney function. Forty-one percent of participants were Black, 40% were White, 21% were Hispanic/Latino, 10% were Asian, and 2% were American Indian/Alaska Native.

The study team assigned participants at random to either taper off MMF over a 12-week period or to remain on their baseline MMF dose. Investigators followed the participants for 60 weeks to monitor if and when they experienced a flare severe or persistent enough to require either new immunosuppressive therapy or higher doses of it. 

By week 60, 9 of 51 participants in the MMF withdrawal group and 5 of 49 in the MMF maintenance group had severe or persistent flares requiring new or increased immunosuppressive therapy. The estimated risk of such flares by week 60—a metric that reflected both occurrence and timing—was up to 18% in the withdrawal group and 11% in the maintenance group. The investigators also looked at five different measures of lupus flares and found that treatment withdrawal consistently led to a 6% to 8% increase in the risk for flares. For participants with a history of kidney disease, the increase in risk was higher, at 14%. One benefit of MMF withdrawal, however, was a reduction in infections. Forty-six percent of the withdrawal group had at least one infection compared with 64% of the maintenance group. 

This study is the first clinical trial of therapy withdrawal in people with SLE who no longer experience symptoms on long-term MMF, according to the researchers. Their findings suggest that MMF may be safely withdrawn in many people with stable SLE, they write, but larger studies and longer follow-up are still needed.

Reference: EF Chakravarty, et al. Mycophenolate mofetil withdrawal in systemic lupus erythematosus patients. The Lancet Rheumatology DOI: 10.1016/S2665-9913(23)00320-X (2024).

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog

Adjuvanticity of a Novel TLR5 Agonist

Description

The NIAID Adjuvant Webinar Series is a monthly virtual presentation given on current research relating to vaccine adjuvants. Each month a new speaker is invited to share their findings with the adjuvant research community. The overall goals of the webinar series are to publicize recent developments in the adjuvant field and to encourage collaboration between adjuvant researchers. Webinars take place on the fourth Tuesday of every month from 12:30 – 1:30 p.m. (ET), with a hiatus during the summer and winter. 

Immune Drivers of Autoimmune Disease (IDAD)

The IDAD program aims to improve our understanding of the immunologic processes underlying the initiation, progression, and clinical course of autoimmune diseases. The research thus focuses on defining the immunologic states and dynamics that drive the development of autoimmune diseases with the goal of preventing autoimmunity or stalling its clinical progression. All IDAD projects are focused solely on human subjects. IDAD researchers will develop and utilize novel approaches that may enhance the feasibility of future large-scale studies by reducing costs and burden to subjects.

Main Areas of Focus

  • To better understand the mechanisms by which genetic variants influence the course, progression, and clinical features of autoimmune diseases
  • To identify biomarkers of flare, remission, and progression of autoimmune disease
  • To investigate the evolution and regulation of immune responses during disease progression or flare
  • To refine molecular-level markers of autoimmune diseases into mechanistic understanding of cellular or humoral immune dysfunction in those diseases
  • To elucidate immunologically distinct endotypes within autoimmune diseases
  • To better understand the mechanisms by which environmental or microbial influences modulate immune responses to result in flare, remission, or progression of disease

IDAD Funded Projects

Content Coordinator

Identify Novel Research Targets to HEAL Opioid Use Disorders

Funding News Edition:
See more articles in this edition

NIAID and other NIH institutes and centers (ICs) are seeking research applications to accelerate NIH’s Helping to End Addiction Long-Term (HEAL) Initiative, which will develop safe and efficacious medications to treat and prevent opioid use disorders through two companion notices of funding opportunities (NOFOs):

The ongoing opioid use and overdose crisis prompts an urgent need to develop new medications by identifying novel research targets and lead molecules to develop therapeutic approaches that will be effective at various stages along the trajectory of opioid use disorders (OUDs); from initiation to chronic use, physical dependence, relapse, and overdose.

Research Scope

The NIH HEAL Initiative NOFOs specifically focus on identifying novel targets and preclinical validation of small molecules and biologics for treating OUDs, opioid overdose, and opioid-polysubstance use comorbidities.

Your proposed studies could include the following:

  • Identification of novel targets for the treatment of OUDs, opioid overdose, and opioid-polysubstance use comorbidities.
  • Discovery and development of small molecule probes and lead compounds for specific novel targets that have been identified as promising targets for OUD and opioid overdose.
  • Studies on the interaction of the hits and probe molecules with the identified targets/pathways.
  • Identification of peptides, biologics (monoclonal antibodies, recombinant proteins), and nucleic acid-based molecules to modulate the expression or function of the identified targets.
  • Studies on target engagement in vivo, mechanism of action, and target selectivity.

The NOFOs provide a longer list of example topics.

NIAID-Specific Research Interests

Synthetic opioids, such as fentanyl, carfentanil, acetylfentanyl, sufentanil, remifentanil, lofentanil, and alfentanil, have also been designated as highly toxic chemicals of concern where medical countermeasures (MCMs) are urgently needed.

Through the Chemical Countermeasures Research Program (CCRP), NIAID supports the research and early-stage development of MCMs to treat and/or prevent serious morbidities and mortality during or after high consequence public health emergencies involving the release of highly toxic chemicals that may result in mass civilian casualty. CCRP is especially interested in novel therapeutic targets and approaches that:

  • Will improve the current post-exposure/overdose standard-of-care therapies to rescue victims of synthetic opioid intoxication more effectively, either alone or in combination with other substances, such as xylazine and nitazenes.
  • Can be deployed easily and rapidly in the field, i.e., amenable to mass casualty use.
  • May be therapeutically effective against one or more of the synthetic opioids of concern listed above.
  • Has a mechanism of action other than antagonizing the mu-opioid receptor.
  • Improves respiratory drive to stimulate reversal of opioid-induced respiration depression (OIRD).

Avoid Proposing These Nonresponsive Research Studies in Your Application

If your application includes studies on the following topics, NIH will consider your application to be nonresponsive and return it to you without review:

  • Studies focused on targets for the discovery of analgesics for pain treatment.
  • Optimizing leads to clinical candidates and drug development efforts.
  • Generating new animal models.
  • Studies that do not focus on the discovery of novel targets or probes for OUD/opioid overdose, or targets involved in comorbidities associated with opioid use combined with other substances.

Include a PEDP in Your Application

The NOFOs require a Plan for Enhancing Diverse Perspectives (PEDP), described in NOT-MH-21-310, submitted as other project information as an attachment (see Section IV).

We strongly encourage applicants to read the NOFO instructions carefully and view the available PEDP guidance material. Peer reviewers will assess the PEDPs as part of the scientific and technical peer review evaluation; we will also consider PEDP among programmatic matters with respect to funding decisions.

Award Information

Application budgets for the R01 NOFO are limited to no more than $400,000 in annual direct costs and need to reflect the actual needs of the proposed project. For R21 applications, the combined budget for direct costs for the 2-year project period may not exceed $275,000. Applicants cannot request more than $200,000 in any single year.

The scope of the proposed project should determine the project period. The maximum project period for an R01 application is 5 years, while the maximum project period for an R21 application is 2 years.

NIAID and its partnering ICs plan to fund between eight and ten awards through both NOFOs.

Both NOFOs have a single application due date: February 1, 2024, at 5 p.m. local time of the applicant organization. 

Contact Information

Direct inquiries to Dr. Dave Yeung, NIAID’s scientific/research contact for both NOFOs, at dy70v@nih.gov or 301-761-7237.

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.

A Secret to Health and Long Life? Immune Resilience, NIAID Grantees Report

NIAID Now |

Do you know some people who almost never get sick and bounce back quickly when they do, while other people frequently suffer from one illness or another? NIAID-supported researchers have pinpointed an attribute of the immune system called immune resilience that helps explain why some people live longer and healthier lives than others.

Immune resilience involves the ability at any age to control inflammation and to preserve or rapidly restore immune activity that promotes resistance to disease, the investigators explain. They discovered that people with the highest level of immune resilience lived longer than others. People with greater immune resilience also were more likely to survive COVID-19 and sepsis as well as to have a lower risk of acquiring HIV infection and developing AIDS, symptomatic influenza, and recurrent skin cancer. In addition, women were more likely to have optimal immune resilience than men. These findings suggest that knowing an individual’s level of immune resilience could help healthcare providers assess the risk for a severe outcome in people with immunity-dependent diseases and identify mechanisms to extend lifespan, according to the investigators. The NIAID co-funded research was published today in the journal Nature Communications.

The nine-year study was led by Sunil Ahuja, M.D., the President's Council/Dielmann Chair for Excellence in Medical Research and professor of medicine at the University of Texas Health Science Center at San Antonio. Dr. Ahuja is also director of research enhancement programs at the university and director of the Veterans Administration Center for Personalized Medicine in the South Texas Veterans Health Care System in San Antonio.

Measuring Immune Resilience

Dr. Ahuja and colleagues developed two ways to measure immune resilience, or IR, one based on immune-cell levels in blood and the other on patterns of genes that are turned on, or expressed. The investigators evaluated these metrics in roughly 48,500 people ages 9 to 103 years who were exposed to pathogens and other immune-system stressors of varied types and severity levels, including the natural aging process. The data on these people, who were Black, Hispanic, or White, came from more than 18 different studies conducted in Africa, Europe and North America.

One of the two IR metrics—the immune health grade, or IHG—is based on the relative quantities of two types of white blood cells, CD8+ T cells and CD4+ T cells, which coordinate the immune system’s response to pathogens and kill other cells that have been infected. CD4+ T-cell counts in the blood have long been used to measure immune health, particularly in people with HIV. The IHG is innovative because it reflects the balance between CD8+ and CD4+ T-cell counts. The CD8+ to CD4+ T-cell balance in optimal IR is called IHG-I, while less optimal levels of IR are called IHG-II, IHG-III and IHG-IV.

The second IR metric is based on two patterns of gene expression: one that best predicted survival and another that best predicted death in two large groups of people after controlling for age and sex. The researchers labeled the survival-associated pattern SAS-1 and the mortality-associated pattern MAS-1. SAS-1 genes are largely related to immune competence—the ability to preserve or rapidly restore immune activity that promotes resistance to disease. MAS-1 genes are largely related to inflammation—the process by which the immune system recognizes and helps kill or remove pathogens and other harmful or foreign substances and begins the healing process. The scientists found that high levels of SAS-1 gene expression and low levels of MAS-1 gene expression indicated that a person had optimal IR and a lower risk of dying prematurely, while the opposite indicated poor IR and a higher risk of premature death. If SAS-1 and MAS-1 levels were both high or both low, IR and risk of premature death were moderate.

The investigators tested these two sets of metrics—IHGs and SAS-1/MAS-1—in the context of low-, moderate- and high-intensity stress to the immune system to determine how well the measures predicted health outcomes and lifespan after controlling for age and sex. The scientists identified groups of people experiencing these different intensities of immune challenges in the context of their daily lives. The group experiencing low-intensity immune stimulation comprised thousands of HIV-negative people ages 18 to 103 years participating in long-term studies of aging. The group experiencing moderate-intensity immune stimulation involved hundreds of HIV-negative people with SARS-CoV-2 infection, autoimmune disease, kidney transplant, or behavioral risk factors for acquiring HIV. Finally, the group experiencing high-intensity immune stimulation comprised thousands of people whose immune systems were responding to HIV replication in the blood soon after infection.

Variations in Immune Resilience

The researchers found that preserving optimal IR, as indicated by having either IHG-I or the combination of high SAS-1 and low MAS-1, was associated with the best health outcomes and longest lifespans. In addition, the risk or severity of negative immunity-dependent health outcomes increased as baseline IR level decreased. The scientists also demonstrated that the proportion of people with optimal IR (IHG-I or high SAS-1/low MAS-1) tended to be highest in the youngest people and lowest in the oldest people. Similarly, the proportion of people with the least optimal IR metrics (IHG-III or IHG-IV and low SAS-1/high MAS-1) tended to be lowest in the youngest age groups and highest in the oldest age groups. However, the investigators found that each of the four immune health grades and related SAS-1/MAS-1 gene expression profiles appeared in people in every age group.

As people age, the researchers explained, increasingly more health conditions such as acute infections, chronic diseases and cancers challenge their immune systems to respond and—ideally—recover. Over time, these challenges degrade most people’s immune health, accounting for the declining proportion of people with IHG-I and high SAS-1/low MAS-1 over the lifespan. However, some people who are 90 years old or more still have IHG-I and high SAS-1/low MAS-1—a reflection of their immune systems’ exceptional capacity to control inflammation and preserve or rapidly restore immune activity associated with longevity despite the many immune health challenges they have faced.

By contrast, the researchers demonstrate that some young adults who are repeatedly exposed to immune threats may have the least optimal IR, as measured by IHG-III or IHG-IV and low SAS-1/high MAS-1. The investigators show how young female sex workers who had many clients and did not use condoms—and thus were repeatedly exposed to sexually transmitted pathogens—had drastically degraded immune health even if they did not acquire HIV. In addition, sex workers with nonoptimal IR, especially those with IHG-IV, had a higher risk of acquiring HIV infection regardless of their level of risk behavior. However, most of the sex workers who began reducing their exposure to sexually transmitted pathogens by using condoms and decreasing their number of sex partners improved to IHG-I over the next 10 years.

The scientists also observed this plasticity of IR in other contexts. For example, the researchers found that most people couldn’t maintain optimal IR when they experienced inflammatory stress from a common symptomatic viral infection like a cold or the flu. In this situation, most people who the investigators studied developed low SAS-1/high MAS-1 within 48 hours of symptom onset, indicating poor IR and a high risk of dying prematurely. As people recovered from their infection, however, many gradually returned to the more favorable SAS-1/MAS-1 levels that they had before. Yet nearly 30 percent of those who had high SAS-1/low MAS-1 before getting sick did not fully regain that survival-associated profile by the end of the cold and flu season, even though they had recovered from their illness.

Interestingly, the investigators also found that the ability to maintain or develop optimal IR during a respiratory virus infection, as measured by high SAS-1/low MAS-1, correlated with an absence of symptoms.

Implications of Immune Resilience

The researchers suggest numerous implications of their findings for personalized medicine, biomedical research, and public health. First, some younger adults have low IR due to unsuspected immunosuppression, whereas some older adults have superior IR. These differences may account for why some younger people are predisposed to disease and shorter lifespans while some elderly people remain unusually healthy and live longer than their peers. Second, reducing exposure to immune stressors may maintain optimal IR or give people with low or moderate IR the opportunity to regain optimal IR, thereby decreasing risk of severe disease. Third, measuring people’s IHG and SAS-1/MAS-1 profile in the early stages of illness could allow for detection of poor IR and initiation of more aggressive therapy. Fourth, it may make sense to balance the intervention and placebo arms of clinical trials by both IR status and common factors such as age and sex when testing interventions dependent on controlling inflammation and preserving or rapidly restoring immune activity associated with longevity. Fifth, developing and implementing strategies to mitigate IR degradation may improve people’s response to vaccination as well as their overall health and lifespan. Finally, strategies for boosting IR and reducing recurrent immune stressors may help address racial, ethnic, and geographic disparities in diseases such as cancer and viral infections like COVID-19.

Reference: SK Ahuja, et al. Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection. Nature Communications DOI: 10.1038/s41467-023-38238-6 (2023).

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog

NIAID-Supported Study Provides Stronger Evidence of Link Between RSV and Childhood Asthma

NIAID Now |

A NIAID-supported study has found that respiratory syncytial virus (RSV) infection in the first year of life is associated with a significantly increased risk of asthma in children. The study was published in the journal The Lancet. These findings provide additional evidence for a casual association between the occurrence of RSV infection in children younger than 1 and an increased incidence of wheezing and asthma in later in life.

RSV is a seasonal respiratory pathogen that affects almost all children by age 2, and repeatedly throughout life. In most children, symptoms of the virus are mild and usually resolve within a week. However, RSV can lead to death or serious illness, especially in premature or very young infants, and those with chronic lung disease or congenital heart disease, although about half of all RSV hospitalizations are among healthy infants. In infants (children younger than 1), RSV is the leading cause of bronchiolitis, a lower respiratory tract infection in infants and young children presenting with coughing and wheezing. Prior evidence on the links between RSV infection in infancy and respiratory health derives from studies of children with severe RSV bronchiolitis, which impacts a minority of children. The population-level asthma risk following RSV infection of any severity has not been studied before.

The “Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure (INSPIRE)” is the first cohort specifically designed to test the hypothesis that not being infected with RSV in infancy decreases the risk of childhood asthma. The population-based cohort study included 1,946 healthy infants born between June and December of 2012 and 2013 who were 6 months old or younger at the beginning of the RSV season (November to March in the study area of Tennessee). Biweekly surveillance and serology tests were used to classify infants as RSV infected or not infected in the first year of life. Of the 1,741 who received classifications, 54% were infected with RSV in the first year of life.

Participants were followed prospectively for five years and then evaluated for 5-year current asthma, which was defined as 1) a parental report of diagnosed asthma or the use of asthma medications before age 5, and 2) any of the following in the 12 months prior to the 5-year visit: asthma symptoms, use of systemic (oral or intravenous) steroids for asthma, or doctor or emergency room visits for asthma symptoms.

The study found that infants who were not infected with RSV in the first year of life had a 26% lower risk of asthma at 5 years of age than those who were infected with RSV as infants. Because the study was observational, the results do not definitively establish causality but do support a need for long-term follow-up of common respiratory outcomes among children in clinical trials of RSV prevention products.

Infancy is a critical time for immune system and pulmonary development; understanding how RSV infection before age 1 is associated with an increased risk of childhood asthma could help to prevent long-term childhood respiratory morbidity.

The study was funded by NIAID, the National Heart, Lung and Blood Institute, the National Center for Advancing Translational Sciences and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Reference: C Rosas-Salazar, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study.

The Lancet DOI: 10.1016/S0140-6736(23)00811-5 (2023)

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog